A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures

Osteoporosis International

Volumn 25, Issue 1, 2014, Pages 51-60

  Si, L ^a   Winzenberg, T M ^a   Palmer, A J ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Economics; Fractures; Model; Osteoporosis; Review

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DECISION TREE; ECONOMIC EVALUATION; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PELVIS FRACTURE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SPINE FRACTURE; SYSTEMATIC REVIEW; TEACHING; TIBIA FRACTURE; WRIST FRACTURE;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMETRIC; OSTEOPOROTIC FRACTURES;

EID: 84891858790     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2551-y     Document Type: Review

References (98)

1. Glaser DL, Kaplan FS (1997) Osteoporosis: definition and clinical presentation. Spine 22:12S-16S (Pubitemid 28123766)
2. Economics A, Australia O (2001) The burden of brittle bones: costing osteoporosis in Australia. Access Economics, Canberra
3. Welfare AIoHa (2011) A snapshot of osteoporosis in Australia 2011. Australian Institute of Health and Welfare, Canberra.
4. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761-1767 (Pubitemid 34614532)
5. Dimai HP, Redlich K, Peretz M, Borgström F, Siebert U, Mahlich J (2012) Economic burden of osteoporotic fractures in Austria. Heal Econ Rev 2:1-10
6. Schwenkglenks M, Lippuner K, Hauselmann HJ, Szucs TD (2005) A model of osteoporosis impact in Switzerland 2000-2020. Osteoporos Int 16:659-671 (Pubitemid 40897464)
7. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521
8. Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38-42 (Pubitemid 38252438)
9. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-380
10. Kanis JA, Johnell O, Oden A et al (2004) The risk and burden of vertebral fractures in Sweden. Osteoporosis international 15:20-26 (Pubitemid 38252435)
11. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1-146
12. Stevenson M, Davis S, Lloyd-Jones M, Beverley C (2007) The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 11:1-134
13. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 21:157-165
14. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK (2001) Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4:348-361 (Pubitemid 32946233)
15. Briggs A, Sculpher M, Claxton K (2006) Decision modelling for health economic evaluation. Oxford University Press, New York
16. Hersh AL, Black WC, Tosteson AN (1999) Estimating the population impact of an intervention: a decision-analytic approach. Stat Methods Med Res 8:311-330 (Pubitemid 30150720)
17. Zethraeus N, Ben Sedrine W, Caulin F et al (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841-857 (Pubitemid 35364785)
18. Zethraeus N, Borgstrom F, Strom O, Kanis JA, Jonsson B (2007) Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 18:9-23 (Pubitemid 44885492)
19. Papapoulos S, Chapurlat R, Libanati C et al (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 27:694-701
20. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
21. Group CaCEM, Centre EfPaPIaC (2013) CCEMG-EPPI-Centre Cost Converter. http://eppi.ioe.ac.uk/costconversion/default.aspx. Accessed 24 Apr 2013
22. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44-47 (Pubitemid 351160875)
23. Jonsson B, Kanis J, Dawson A, Oden A, Johnell O (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193-199 (Pubitemid 29458713)
24. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax (registered trademark)) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305-314 (Pubitemid 36403435)
25. Borgstrom F, Carlsson A, Sintonen H, Boonen S, Haentjens P, Burge R, Johnell O, Jonsson B, Kanis JA (2006) The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17:996-1007 (Pubitemid 43864853)
26. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061 (Pubitemid 47020004)
27. Tosteson ANA, Jönsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD (2001) Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 12:849-857 (Pubitemid 33086272)
28. Thompson M, Pasquale M, Grima D, Moehrke W, Kruse HP (2010) The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis. Value Health 13:46-54
29. Alzahouri K, Bahrami S, Durand-Zaleski I, Guillemin F, Roux C (2013) Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX (trademark) thresholds for decision. Joint Bone Spine 80:64-69
30. Fleurence RL (2004) Cost-effectiveness of fracture prevention treatments in the elderly. Int J Technol Assess Health Care 20:184-191 (Pubitemid 38685950)
31. Tosteson ANA, Burge RT, Marshall DA, Lindsay R (2008) Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manage Care 14:605-615
32. Strom O, Borgstrom F, Kleman M, McCloskey E, Oden A, Johansson H, Kanis JA (2010) FRAX and its applications in health economics-cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47:430-437
33. Stevenson MD, Brazier JE, Calvert NW, Lloyd-Jones M, Oakley JE, Kanis JA (2005) Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J Oper Res Soc 56:214-221 (Pubitemid 40212817)
34. Nayak S, Roberts MS, Greenspan SL (2011) Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med 155:751-761
35. Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ III (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042-1049 (Pubitemid 34105976)
36. Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, Jonsson B (2005) Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16:15-25 (Pubitemid 40193215)
37. Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H (2007) Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 23:2517-2529 (Pubitemid 350033454)
38. Hiligsmann M, Ethgen O, Bruyere O, Reginster JY (2008) An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Disease Management and Health Outcomes 16:429-438
39. Wasserfallen JB, Krieg MA, Greiner RA, Lamy O (2008) Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective. J Med Econ 11:499-523
40. Hiligsmann M, Ethgen O, Bruyere O, Richy F, Gathon HJ, Reginster JY (2009) Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12:687-696
41. Hiligsmann M, Reginster JY (2010) Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47:34-40
42. Murphy DR, Smolen LJ, Klein TM, Klein RW (2012) The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC musculoskelet Disord 13:213-213
43. Hiligsmann M, Bruyere O, Reginster JY (2010) Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 46:440-446
44. Hiligsmann M, Reginster JY (2011) Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29:895-911
45. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY (2012) The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15:604-612
46. Ding H, Koinuma N, Stevenson M, Ito M, Monma Y (2008) The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis. J Bone Miner Metab 26:34-41 (Pubitemid 350308007)
47. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862-871 (Pubitemid 39506452)
48. Borgstrom F, Johnell O, Kanis JA et al (2006) At what hip fracture risk is it cost-effective to treat?: international intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17:1459-1471 (Pubitemid 44387481)
49. Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21:495-505
50. Akehurst R, Brereton N, Ariely R, Lusa T, Groot M, Foss P, Boonen S (2011) The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ 14:53-64
51. Borgstrom F, Strom O, Kleman M, McCloskey E, Johansson H, Oden A, Kanis JA (2011) Cost-effectiveness of bazedoxifene incorporating the FRAX(R) algorithm in a European perspective. Osteoporos Int 22:955-965
52. Kanis JA, Adams J, Borgstrom F, Cooper C, Jonsson B, Preedy D, Selby P, Compston J (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4-15
53. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M (1992) HRT: an analysis of benefits, risks and costs. Br Med Bull 48:368-400
54. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY (2010) Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13:394-401
55. Cundy T, Cornish J, Evans MC, Gamble G, Stapleton J, Reid IR (1995) Sources of interracial variation in bone-mineral density. J Bone Miner Res 10:368-373
56. Ross PD, He YF, Yates AJ, Coupland C, Ravn P, McClung M, Thompson D, Wasnich RD (1996) Body size accounts for most differences in bone density between Asian and Caucasian women. Calcif Tissue Int 59:339-343 (Pubitemid 26367080)
57. Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967-982
58. Sculpher M, Fenwick E, Claxton K (2000) Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics, 17(5):461-477 (Pubitemid 30398805)
59. Soto J (2002) Health economic evaluations using decision analytic modeling. Principles and practices - utilization of a checklist to their development and appraisal. Int J Technol Assess Health Care 18:94-111 (Pubitemid 34408532)
60. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices - modeling studies. Value Health 6:9-17 (Pubitemid 36228345)
61. Sonnenberg FA, Beck JR (1993) Markov-models in medical decision-making: a practical guide. Med Decis Mak 13:322-338 (Pubitemid 24013155)
62. Palmer AJ, Stephane R, Valentine WJ, Minshall ME et al (2004) Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 20:S27-S40 (Pubitemid 39349906)
63. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. PharmacoEconomics 13:397-397 (Pubitemid 28140699)
64. van Staa TP, Kanis JA, Geusens P, Boonen A, Leufkens HG, Cooper C (2007) The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 10:348-357 (Pubitemid 47481106)
65. Schousboe JT, Ensrud KE, Nyman JA, Melton LJ III, Kane RL (2005) Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 53:1697-1704 (Pubitemid 43109932)
66. Cotte FE, De Pouvourville G (2011) Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res 11:151
67. Akehurst R, Dixon S, Fryback D et al (2000) Decision analytic modelling in the economic evaluation of health technologies: a consensus statement. PharmacoEconomics 17:443-443
68. Gold M, Siegel J, Russell L, Weistein M (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
69. Hay J, Jackson J, Luce B, Avorn J, Ashraf T (1999) Panel 2: methodological issues in conducting pharmacoeconomic evaluations - modeling studies. Value Health 2:78-81
70. Cleemput I, van Wilder P, Huybrechts M, Vrijens F (2009) Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 12:441-449
71. Gandjour A, Weyler EJ (2008) Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany. Value Health 11:1088-1095
72. Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET (2010) Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US. PharmacoEconomics 28:395-395
73. Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, Bonsel G, van der Kuy A (1998) Reporting format for economic evaluation. Part II: focus on modelling studies. PharmacoEconomics 14:259-259 (Pubitemid 28416930)
74. Buxton MJ, Drummond MF, Van Hout BA, Prince RL, Sheldon TA, Szucs T, Vray M (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6:217-227 (Pubitemid 27296586)
75. Sonnenberg FA, Roberts MS, Tsevat J, Wong JB, Barry M, Kent DL (1994) Toward a peer review process for medical decision analysis models. Med Care 32:JS52-JS64
76. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739 (Pubitemid 30174026)
77. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B (2004) Fracture risk following an osteoporotic fracture. Osteoporos Int 15:175-179 (Pubitemid 38391531)
78. Lundkvist J, Johnell O, Cooper C, Sykes D (2006) Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 17:201-211 (Pubitemid 43053582)
79. Borgstrom F, Strom O, Marin F, Kutahov A, Ljunggren O (2010) Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis. J Med Econ 13:381-392
80. Weinstein MC (1980) Estrogen use in postmenopausal women - costs, risks, and benefits. N Engl J Med 303:308-316 (Pubitemid 10040019)
81. Tosteson AN, Rosenthal DI, Melton LJ III, Weinstein MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603 (Pubitemid 20346189)
82. Weinstein MC, Tosteson ANA (1990) Cost-effectiveness of hormone replacement. Ann N Y Acad Sci 592:162-172 (Pubitemid 20273215)
83. Tosteson ANA, Weinstein MC (1991) Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 5:943-959
84. Cheung AP, Wren BG (1992) A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156:312-316
85. Zethraeus N, Borgstrom F, Jonsson B, Kanis J (2005) Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the women's health initiative randomized controlled trial. Int J Technol Assess Health Care 21:433-441 (Pubitemid 41642834)
86. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK (2006) Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Mak 26:194-206
87. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333 (Pubitemid 34761611)
88. Neer RM, Genant HK, Wang O et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441 (Pubitemid 32402100)
89. Deil IJ, Bergner R, Grotz KA (2007) Adverse effects of bisphosphonates: current issues. J Support Oncol, 5:475-482
90. Woo S-B, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761 (Pubitemid 46780635)
91. Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE (1989) Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis. Bone 10:3-6 (Pubitemid 19134737)
92. Ettinger B, Pressman A, Schein J (1998) Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manage Care 4:1377-1382 (Pubitemid 28506801)
93. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1998) Lifetime risk of hip fractures is underestimated. Osteoporos Int 8:599-603 (Pubitemid 28566977)
94. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468-473 (Pubitemid 39665705)
95. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY (2010) The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96:170-177
96. Singh S, Sun H, Anis AH (2004) Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol 31:1607-1613 (Pubitemid 39006644)
97. Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313:275-283 (Pubitemid 26254740)
98. Husereau D, Loder E, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ 14:367-372